Business
Beam Therapeutics Presents Recently Reported Topline Clinical Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the American Thoracic Society (ATS) 2026 International Conference
Presentation Features Additional Data from the Single-dose Cohorts of the Phase 1/2 Trial, Including Detailed Safety Results, Efficacy Durability and Reduction in Human Neutrophil Elastase Activity Post-BEAM-302 TreatmentCAMBRIDGE, Mass., May 18, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today presented the recently reported clinical data from the BEAM-302 Phase 1/2 trial in alpha-1 antitry
About this update from Beam Therapeutics Inc.
[{"type":"image","alt":"Beam logo","displaySize":"","headline":null,"caption":"Beam logo","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":154,"url":"https://media.zenfs.com/en/globenewswire.com/9d2ec020ecd101e1c60cc6fb1efb6fdb"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/MVnQbWAEvrVhOJdyJ1L51Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIxNg--/https://media.zenfs.com/en/globenewswire.com/9d2ec020ecd101e1c60cc6fb1efb6fdb","width":300,"height":154},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/MVnQbWAEvrVhOJdyJ1L51Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIxNg--/https://media.zenfs.com/en/globenewswire.com/9d2ec020ecd101e1c60cc6fb1efb6fdb","width":300,"height":154}},"lazy":false},{"type":"text","content":"Presentation Features Additional Data from the Single-dose Cohorts of the Phase 1/2 Trial, Including Detailed Safety Results, Efficacy Durability and Reduction in Human Neutrophil Elastase Activity Post-BEAM-302 Treatment","length":221,"tagName":"p"},{"type":"text","content":"CAMBRIDGE, Mass., May 18, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today presented the recently reported clinical data from the BEAM-302 Phase 1/2 trial in alpha-1 antitrypsin deficiency (AATD) at a symposium on translating scientific discovery in gene editing into clinical progress for patients with lung disease. The presentation was given by Amy Simon, M.D., chief medical officer of Beam, at the American Thoracic Society (ATS) International Conference being held in Orlando, Fla.","length":593,"tagName":"p"},{"type":"text","content":"“At Beam, we are committed to leading innovation in the AATD community, with a goal of transforming disease outcomes for all patients suffering from this disease,” said Dr. Simon. “For BEAM-302, the data shared today build on the growing body of clinical evidence that supports the profound impact of treating AATD at the root cause of disease, the DNA mutation, with this one-time investigational therapy. We are rapidly executing toward pivotal development to deliver BEAM-302 to patients with AATD as safely and expeditiously as possible. Our long-term goal is to combine our growing understanding of AATD biology and our leading gene editing capabilities to maximize patient benefit across the entire spectrum of ...